Zymeworks
ZYME
26.14
-0.72
-2.68%
Zymeworks
US · ZYME
#2828 by market cap
Listed 2017
26.14
-0.72
-2.68%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Zymeworks
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
- Founded
- 2003
- CEO
- Mr. Kenneth Galbraith
- Employees
- 264
- Headquarters
- Middletown, Delaware, United States of America
- Fiscal year end
- 12-31
- Website
- zymeworks.com
Company profile
- Exchange
- US
- Symbol
- ZYME
- Market-cap rank
- #2828
- Listing date
- 2017-04-28
- Market cap
- 1.81B
- Float cap
- 1.69B
- Shares out
- 69.17M
- Float shares
- 64.69M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Zymeworks discussion 0 comments